Antiangiogenic pharmaceutical composition comprises, as active ingredient, one or more of: (i) nucleic acid (I) from an endothelial cell gene the expression of which is induced by an angiogenic agent, or its complement or fragment； (ii) polypeptide (II) encoded by (I), or its fragment； (iii) an antisense nucleic acid (III) able to inhibit expression of (I)； or (iv) an antibody (Ab) that binds (II). Independent claims are also included for the following: (1) antibody (Ab1) with affinity for any of 9 specified protein sequences (A), reproduced or their fragments； (2) producing Ab1 by in vitro immunization of an immunocompetent cell, especially from a mammal, with any of (A) or their fragments； (3) composition for diagnosis, prognosis and/or treatment of angiogenesis-related diseases comprising Ab1 or its fragments； (4) antisense sequences (IIIa) containing at least 10 nucleotides (nt) from any of 9 nucleic acid sequences (B) reproduced； (5) mammalian expression vector containing at least one (IIIa)； (6) mammalian expression vector containing any of (B) or their fragments； (7) preparing a cell that underexpresses a gene implicated in an angiogenic disease comprising inserting a vector of (5) or (6) into a mammalian cell； (8) genetically modified cell that under- or over-expresses a (B)； (9) preparing a cell line that stably expresses a vector of (5) or (6)； (10) composition for diagnosis, prognosis and/or treatment of angiogenic diseases in mammals containing a cell of (8) or (9)； (11) preparing a recombinant protein by cloning a (B) into a vector and introducing the product into a host cell； (12) recombinant protein or its fragments, produced by method (11) and compositions containing it； (13) diagnosis and/or prognosis of angiogenic diseases by detecting over- or under-expression of (B), in vitro or in isolated cells； (14) verifying effect of angiogenic treatment by in vitro detection of cell populations that under- or over-express at least one (B)； (
